ery and
therapeutics aimed at specific disease targets. The Company, with
laboratories and headquarters in Huntsville, Alabama, is focused on
developing therapeutics for the treatment of human diseases including
cancer and cardiovascular disease. The Company has a significant
intellectual property position in biocompatible polymers, their novel
compositions with nucleic acids, and their therapeutic applications. EGEN
has research pipeline products aimed at treatment of various cancers and
cardiovascular disease involving siRNA, shRNA, tumor antigens, and
angiogenic genes. EGEN has collaborations with outside investigators,
biotech organizations and universities on various projects in these areas.
Safe Harbor for Forward Looking Statements
Certain statements contained in this press release may be deemed to be
forward looking statements under federal securities laws and Expression
Genetics intends that such forward looking statements be subject to the
safe harbor created thereby. Expression Genetics does not undertake an
obligation to publicly update or revise any forward looking statements,
whether as a result of new information, future events or otherwise. Actual
events or results may differ from our expectations as a result of a number
of factors, including but not limited to uncertainties in clinical trials
and product development programs, ability and success level of the Company
in securing adequate capital for operations, market place acceptance of any
resulting product and other factors common to biotechnology research and
development. There can be no guarantee that any product in our pipeline
will be successfully developed.
Further information about Expression Genetics can be found at:
http://www.egencorp.com
'/>"/>SOURCE Expression Genetics, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award2.
Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award3.
Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 21554.
Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 165.
ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics6.
Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies7.
Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests8.
deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 20089.
Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs10.
deCODE genetics Announces Second Quarter 2008 Financial Results11.
Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results